Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)

Next Previous
Search
Trial Profile

OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Perindopril/amlodipine
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms OLMAML
  • Sponsors Menarini

    • Most Recent Events

    • 25 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
    • 24 May 2016 Results (post hoc analysis of a substudy) comparing effect of olmesartan/amlodipine versus perindopril/amlodipine published in the American Journal of Hypertension.
    • 15 Jun 2015 Primary endpoint Office diastolic blood pressure has been met as per results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top